MFDS recommends restricted usage of Hanmi’s Olita Tab for terminal cancer patients
The Ministry of Food and Drug Safety(MFDS) recommended restricted usage of the Hanmi Pharm’s non-small cell lung cancer therapy ‘Olita Tab,’ which had a death patient during clinical trials, for terminal cancer patients, instead of taking extreme measures, such as revocation of approval.
The ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
